Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30038200 | 1.00 | KDM4E (0.49) | KDM4EMAPTGAATSHRMAPK1 | |
| SCHEMBL3597728 | 0.92 | MAPT (0.53) | KDM4EMAPTGAATSHRMAPK1 | |
| SCHEMBL9367414 | 0.88 | GAA (0.40) | KDM4EMAPTGAATSHRMAPK1 | |
| SCHEMBL9367884 | 0.84 | KDM4E (0.45) | KDM4EMAPTGAATSHRMAPK1 | |
| SCHEMBL2438047 | 0.81 | KDM4E (0.67) | KDM4EMAPTGAATSHRMAPK1 | |
| SCHEMBL77823 | 0.81 | KDM4E (0.67) | KDM4EMAPTGAATSHRMAPK1 | |
| SCHEMBL29377777 | 0.81 | KDM4E (0.67) | KDM4EMAPTGAATSHRMAPK1 | |
| SCHEMBL20681623 | 0.79 | MAPT (0.51) | KDM4EMAPTGAATSHRMAPK1 | |
| Ammonia Solution, Strong SCHEMBL5361377 | 0.79 | KDM4E (0.64) | KDM4EMAPTGAATSHRMAPK1 | |
| Methane SCHEMBL27340305 | 0.79 | KDM4E (0.64) | KDM4EMAPTGAATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658138-B1 | SUBSTITUTED-3H-IMIDAZO(4,5-C)PYRIDINE AND 1H-PYRROLO(2,3-C)PYRIDINE SERIES OF NOVEL ECTONUCLEOTIDE PYROPHSPHATASE/PHOSPHODIESTRASE-1 (ENPP1) AND STIMULATOR FOR INTERFERON GENES (STING) MODULATOR AS CANCER IMMUNOTHERAPEUTICS | STINGRAY THERAPEUTICS INC (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-3436436-B1 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2022-05-11 | — | — | EP | disclosed |
| EP-3436436-B1 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2022-05-11 | — | — | EP | disclosed |
| US-11180450-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11180450-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3907218-A1 | 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-11-10 | — | — | EP | disclosed |
| US-11142524-B2 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. (US) | 2021-10-12 | — | — | US | disclosed |
| US-11142524-B2 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. (US) | 2021-10-12 | — | — | US | disclosed |
| US-11083707-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| US-11083707-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20100048569-A1 | DIAZOLE DERIVATIVES | BUETTELMANN BERND | 2010-02-25 | — | — | US | disclosed |
| EP-1756086-B1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1539744-A4 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARM INC (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1756086-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-20060030559-A1 | Diazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2005118568-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-15 | — | — | WO | disclosed |
| EP-1539744-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004007444-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048569-A1 | DIAZOLE DERIVATIVES | GRM1, GRM2, GRIN2B | KDM4E 2704/4885MAPT 1397/4885GAA 1279/4885 |
| US-20060030559-A1 | Diazole derivatives | GRM1, GRM2, GRIN2B | KDM4E 2704/4885MAPT 1397/4885GAA 1279/4885 |
| US-11180450-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | IDO1, INMT, IRF3 | KDM4E 1020/4885MAPT 1807/4885GAA 2965/4885 |
| US-11083707-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | IDO1, IRF3, INMT | KDM4E 993/4885MAPT 1818/4885GAA 2865/4885 |
| US-11142524-B2 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | STING1, ENPP1, CGAS | KDM4E 1284/4885MAPT 4738/4885GAA 607/4885 |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | KDM4E 2323/4885MAPT 3703/4885GAA 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.